Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Travere Therapeutics, Inc.

< Previous 1 2 3 4 Next >
Travere Therapeutics to Report First Quarter 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers ASX:CSL CSLLY TVTX
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers ASX:CSL CSLLY TVTX
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Provides Corporate Update and 2024 Outlook
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Third Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Report Third Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers MIRM TVTX
Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Second Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.